Pegpleranib Sodium

Summary

Pegpleranib Sodium (CHEMBL3301576) is a phase-3 clinical-stage unknown; indicated across 2 conditions including age-related macular degeneration and von hippel-lindau disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3301576
Name	Pegpleranib Sodium
Type	Unknown
Max phase	3

Also known as: E-01AJ, E-10030, E01AJ, E10030, Fovista, Pegpleranib sodium, X-01E, X01E, PEGPLERANIB SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
age-related macular degeneration	3	MONDO:0005150	EFO:0001365
von Hippel-Lindau disease	1	MONDO:0008667	MONDO:0008667

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	3
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01940887	PHASE3	TERMINATED	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
NCT01940900	PHASE3	TERMINATED	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
NCT01944839	PHASE3	TERMINATED	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
NCT02859441	PHASE1/PHASE2	COMPLETED	A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
NCT00569140	PHASE1	COMPLETED	A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).